4.7 Article

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Meta-analysis: Pharmacologic treatment of obesity

ZP Li et al.

ANNALS OF INTERNAL MEDICINE (2005)